<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LA) and beta2-glikoprotein I (b2GPI) dependent anti-<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> (aCL) are part of the diagnostic criteria both of <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) and anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> syndrome (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>Anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibodies (aPL) may also bind to other <z:chebi fb="1" ids="16247">phospholipids</z:chebi> and/or protein co-factors </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, besides aCL and anti-b2GPI, antibodies directed against phosphatidylserine, prothrombin (PT) and annexin V (aANX) were measured in 85 randomly selected SLE patients, 14 suffering from secondary APS </plain></SENT>
<SENT sid="3" pm="."><plain>LA was detected by hemostasis tests </plain></SENT>
<SENT sid="4" pm="."><plain>Correlations were determined between rare aPLs and clinical manifestations, including thrombotic events </plain></SENT>
<SENT sid="5" pm="."><plain>Anti-<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> IgG was positive in 14 patients, aCL IgM in 8, anti-b2GPI IgG in 4 and IgM in 5 patients </plain></SENT>
<SENT sid="6" pm="."><plain>LA was detected in nine cases </plain></SENT>
<SENT sid="7" pm="."><plain>Seven patients were positive for anti-phosphatidylserine (aPS) IgG, nine for aPS IgM, while anti-PT (aPT) IgG was positive in nine cases </plain></SENT>
<SENT sid="8" pm="."><plain>aPT IgM and anti-aANX were negative in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="9" pm="."><plain>Correlation was found between aPS and aCL antibodies </plain></SENT>
<SENT sid="10" pm="."><plain>The frequency and concentration of rare anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi>/co-factor antibodies was higher in patients with secondary APS </plain></SENT>
<SENT sid="11" pm="."><plain>The presence of such rare aPLs cumulated in APS patients, their presence increased the frequency of thrombotic events in the entire study population, furthermore in patients positive for LA or aCL </plain></SENT>
<SENT sid="12" pm="."><plain>Rare anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi>/co-factor antibodies were found in 12% of an un-selected <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> patient population </plain></SENT>
<SENT sid="13" pm="."><plain>Their presence was more frequent in patients with secondary APS, and further increased the risk of thrombotic complications </plain></SENT>
</text></document>